Company* |
Company* |
Product | Terms/Details (Date) |
| | |||
Agencourt |
Amplicon Express Inc.* |
Alliance to co-market a suite of BAC library construction and sequencing services |
Each will provide technology to the effort focused on bacteria artificial chromosomes, which are vectors designed to clone DNA fragments (3/21) |
Ambion |
AcroMetrix Corp.* |
AcroMetrix will manufacture Armored RNA- based products and distribute them to laboratories and manufacturers |
Ambion will supply AcroMetrix custom products based on the Armored RNA technology for further development; terms were not disclosed (3/16) |
Auxilium |
Oscient Pharmaceuticals Corp. (OSCI) |
Two-year deal to co-promote Auxilium's marketed product Testim in the U.S. for treating hypogonadism |
Oscient will promote Testim to primary care physicians, and share profits from those sales above a pre-determined base- line (4/13) |
BioBalance |
Benchmark Biolabs Inc.* |
Benchmark will manufacture ProBactrix for clinical trials |
The product is a live strain of E. coli M-17 being developed for gastrointestinal disorders; terms were not disclosed (3/14) |
Biomedical |
Hemosol Corp. (Canada; HMSL) |
Hemosol will produce the iron-binding drugs 40SD02 and 25SD04 for Biomedical |
The injectable drug formulations will be used for preclinical and clinical studies in iron poisoning, iron overload and diabetic complications; terms were not disclosed (4/4) |
EDC |
Aurora Discovery Inc.* |
Deal to co-market EDC's acoustic liquid-handling instrumentation and Aurora's ChemLib microplates |
Terms of the deal were not disclosed (3/21) |
Halozyme |
Peregrine |
Deal for the manufacture of a Halozyme recombinant human enzyme, which will be used in its Cumulase and Enhanze SC producs |
The manufacturing will be performed by Peregrine subsidiary Avid Bioservices Inc.; terms of the deal were not disclosed (2/17) |
Hawaii Biotech |
Cobra Bio- manufacturing plc (UK;LSE:CBF) |
Cobra will manufacture materials for clinical trials of vaccines against dengue fever and West Nile disease |
Terms of the deal were not disclosed; trials of the recombinant subunit vaccine candidates are expected to begin in 2006 (3/2) |
Inyx Inc. |
Kos Pharmaceuticals Inc. (KOSP) |
10-year deal under which Inyx will produce Kos' Azmacort Inhalation Aerosol product line |
Inyx said the deal is expected to generate about $10M in annual revenues (4/15) |
Omnia |
AT-GC BioPharm Inc.* |
Deal to develop AT-GC Electronic Eye technology for the manufacture of biopharmaceuticals |
They will work together to provide the technology under undisclosed terms (3/24) |
Quantum Dot |
Chemicon International (subsidiary of Serologicals Corp.; SERO) |
Chemicon got rights to market specific quantum dot-containing products for detecting antibody-antigen interactions in immunological experiments |
The deal adds secondary antibody detection technologies to Chemicon's general reagents product portfolio; terms were not disclosed (3/4) |
| | |||
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | |||
